UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 8, 2017
Clovis Oncology, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-35347 | 90-0475355 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
| 5500 Flatiron Parkway, Suite 100 Boulder, Colorado |
80301 | |||
| (Address of principal executive offices) |
(Zip Code) | |||
Registrant’s telephone number, including area code: (303) 625-5000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders
The Annual Meeting of Shareholders (the “Annual Meeting”) of Clovis Oncology, Inc. (the “Company”) was held on June 8, 2017. At the Annual Meeting, the shareholders of the Company voted on the following two proposals and cast their votes as described below.
Proposal One
The individuals listed below were elected at the Annual Meeting to serve a three-year term on the Company’s Board of Directors.
| For |
Withheld |
Broker Non-Votes | ||||
| Keith Flaherty, M.D. |
29,945,650 | 590,325 | 7,876,004 | |||
| Ginger L. Graham |
29,915,559 | 620,416 | 7,876,004 | |||
| Edward J. McKinley |
29,993,513 | 542,462 | 7,876,004 |
Proposal Two
Proposal two was to ratify the appointment of Ernst & Young LLP as auditors of the Company for fiscal year 2017, as described in the proxy materials. This proposal was approved.
| For |
Against |
Abstained |
||||
| 38,120,581 |
87,285 | 204,113 |
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CLOVIS ONCOLOGY, INC. | ||||||
| June 8, 2017 | By: | /s/ Patrick J. Mahaffy | ||||
| Name: | Patrick J. Mahaffy | |||||
| Title: | President and Chief Executive Officer | |||||
- 3 -